Education
About Us
Working with TipRanks
Follow Us
Infant Bacterial Therapeutics AB (DE:9IB)
BERLIN:9IB
9IB Stock Chart & Stats
Day’s Range― - ―
52-Week Range€2.78 - €10.95
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€44.83M
Enterprise Value€223.75M
Total Cash (Recent Filing)kr540.51M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.25
Next Earnings
May 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding13,018,137
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10837.29
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
9IB FAQ
What was Infant Bacterial Therapeutics AB’s price range in the past 12 months?
Infant Bacterial Therapeutics AB lowest stock price was €2.78 and its highest was €10.95 in the past 12 months.
What is Infant Bacterial Therapeutics AB’s market cap?
Infant Bacterial Therapeutics AB’s market cap is €44.83M.
When is Infant Bacterial Therapeutics AB’s upcoming earnings report date?
Infant Bacterial Therapeutics AB’s upcoming earnings report date is May 07, 2025 which is in 57 days.
How were Infant Bacterial Therapeutics AB’s earnings last quarter?
Infant Bacterial Therapeutics AB released its earnings results on Feb 13, 2025. The company reported -€0.228 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.228.
Is Infant Bacterial Therapeutics AB overvalued?
According to Wall Street analysts Infant Bacterial Therapeutics AB’s price is currently Overvalued.
Does Infant Bacterial Therapeutics AB pay dividends?
Infant Bacterial Therapeutics AB does not currently pay dividends.
What is Infant Bacterial Therapeutics AB’s EPS estimate?
Infant Bacterial Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Infant Bacterial Therapeutics AB have?
Infant Bacterial Therapeutics AB has 13,018,137 shares outstanding.
What happened to Infant Bacterial Therapeutics AB’s price movement after its last earnings report?
Infant Bacterial Therapeutics AB reported an EPS of -€0.228 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.305%.
Which hedge fund is a major shareholder of Infant Bacterial Therapeutics AB?
Currently, no hedge funds are holding shares in DE:9IB
---
Company Description
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB is a pharmaceutical company that develops drugs influencing the human infant microbiome, and thereby prevents or treats rare diseases affecting premature infants. It is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants.
---
Technical Analysis
---